Robbert Jan Verkes

Robbert Jan Verkes

Auto-generated profile, based on publicly available information

Robbert Jan Verkes

Dept of psychiatry, RadboudUMC Nijmegen

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Addiction
Verified
Journal Article
Open access
PDF file
TKT Knuijver
T Knuijver
ASArnt F. A Schellekens
Arnt F. A Schellekens
MBMaarten Belgers
Maarten Belgers
RDR Donders
R Donders
TOT van Oosteren
T van Oosteren
RVR J Verkes
R J Verkes
Background and aims: Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non‐medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine in patients with opioid use disorder.Design: A descriptive open‐label observational study.Setting: Department of psychiatry in a university medical center, the Netherlands.Participants: Patients with opioid use disorder (n = 14) on opioid maintenance treatment with a lasting wish for abstinence, who failed to reach abstinence with standard care.Intervention and measurements: After conversion to morphine‐sulphate, a single dose of ibogaine‐HCl 10 mg/kg was administered and patients were monitored at regular intervals for at least 24 hours assessing QTc, blood pressure and heart rate, scale for the assessment and rating of ataxia (SARA) to assess cerebellar side effects and the delirium observation scale (DOS) to assess psychomimetic effects.Findings: The maximum QTc (Fridericia) prolongation was on average 95ms (range 29‐146ms). Fifty percent of subjects reached a QTc of over 500ms during the observation period. In six out 14 subjects prolongation above 450ms lasted beyond 24 hours after ingestion of ibogaine. No torsades des pointes were observed. Severe transient ataxia with inability to walk without support was seen in all patients. Withdrawal and psychomimetic effects were mostly well‐tolerated and manageable (11/14 did not return to morphine within 24 hours, DOS scores remained below threshold).Conclusions: This open‐label observational study found that ibogaine treatment of patients with opioid use disorder can induce a clinically relevant but reversible QTc prolongation, bradycardia, and severe ataxia.

29 January 2002 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
HGHarm J. Gijsman
Harm J. Gijsman
JGJoop M. A. van Gerven
Joop M. A. van Gerven
RVRobbert Jan Verkes
Robbert Jan Verkes
RSRik C. Schoemaker
Rik C. Schoemaker
MPMonique S. M. Pieters
Monique S. M. Pieters
ACAdam F. Cohen
Adam F. Cohen

10 November 2026 in Criminal Behaviour and Mental Health
Verified
Journal Article
Closed access
OBOscar Bloem
Oscar Bloem
EBErik Bulten
Erik Bulten
RVRobbert Jan Verkes
Robbert Jan Verkes